Use of Conditionally Essential Amino Acids and the Economic Burden of Postoperative Complications After Fracture Fixation: Results from a Cost Utility Analysis.

To measure the economic impact of conditionally essential amino acids (CEAA) among patients with operative treatment for fractures. A decision tree model was created to estimate changes in annual health care costs and quality of life impact due to complications after patients underwent operative treatment to address a traumatic fracture. The intervention of interest was the use of CEAA alongside standard of care as compared to standard of care alone. Patients were required to be aged ≥18 and receive the surgery in a US Level 1 trauma center. The primary outcomes were rates of post-surgical complications, changes in patient quality adjusted life years (QALYs), and changes in cost. Cost savings were modeled as the incremental costs (in 2022 USD) of treating complications due to changes in complication rates. The per-patient cost of complications under CEAA use was $12,215 compared to $17,118 under standard of care without CEAA. The net incremental cost savings per patient with CEAA use was $4902, accounting for a two-week supply cost of CEAA. The differences in quality-adjusted life years (QALYs) under CEAA use and no CEAA use was 0.013 per person (0.739 vs 0.726). Modeled to the US population of patients requiring fracture fixations in trauma centers, the total value of CEAA use compared to no CEAA use was $316 million with an increase of 813 QALYs per year. With a gain of 0.013 QALYs per person, valued at $150,000, and the incremental cost savings of $4902 resulted in net monetary benefit of $6852 per patient. The incremental cost-effectiveness ratio showed that the use of CEAA dominated standard of care. CEAA use after fracture fixation surgery is cost saving. Level of Evidence: Level 1 Economic Study.

Informations de copyright

© 2023 Shafrin et al.

Déclaration de conflit d'intérêts

Dr Jason Shafrin, Ms Kyi-Sin Than and Ms. Anmol Kanotra are employees of FTI Consulting which received funding from Abbott Laboratories. Dr Kirk W Kerr and Dr Katie N Robinson are employees of Abbott Nutrition. Dr Michael C Willey reports grants from Orthopaedic Trauma Association, Centers for Disease Control, Arthritis Foundation, Department of Defense, and Excere Inc, outside the submitted work; and this secondary analysis of a previous clinical trial was supported by Abbott Laboratories that produces the nutrition supplement (Juven) used as the intervention. The authors report no other conflicts of interest in this work.